Pfiz­er, the new mas­ter of mR­NA de­liv­ery, teams up with Beam to ship base ed­i­tors straight to tar­get tis­sues

Awash in cash from its Covid-19 vac­cine and lean­er than ever, Pfiz­er has pick of the lit­ter in biotech for deals set to shape its port­fo­lio for the next 10 to 15 years. Gene edit­ing has a ton of mo­men­tum right now, and Pfiz­er is bit­ing in a big way on a buzzy up­start work­ing on “CRISPR 2.0.”

Pfiz­er will pay $300 mil­lion up­front and up to $1.05 bil­lion in ad­di­tion­al down­stream mile­stones to Beam Ther­a­peu­tics as part of a four-year re­search col­lab­o­ra­tion to de­vel­op base ed­i­tors for a trio of ther­a­peu­tic tar­gets in­clud­ing the liv­er, CNS and mus­cle, the part­ners said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER